A synthetic NCAM-derived mimetic peptide, FGL, exerts anti-inflammatory properties via IGF-1 and interferon-gamma modulation

Area of Science:

• Neuroscience
• Immunology
• Aging Research

Background:

• Microglial cell activation increases in the rat hippocampus during normal brain aging.
• The neural cell adhesion molecule (NCAM)-derived mimetic peptide, FG loop (FGL), demonstrates anti-inflammatory properties in the aged rat hippocampus.
• FGL promotes CD200 ligand expression and reduces glial activation and pro-inflammatory cytokine production.

Purpose of the Study:

• To investigate if FGL corrects age-related imbalances in hippocampal insulin-like growth factor-1 (IGF-1) and interferon-gamma (IFNgamma).
• To determine if FGL attenuates age-associated glial reactivity.
• To elucidate the mechanism of FGL's action on neuronal and glial cells.

Main Methods:

• Administration of FGL to aged rats and assessment of hippocampal IGF-1 and IFNgamma levels.
• In vitro studies using primary neurons to assess FGL's effect on IGF-1 release and neuronal Akt phosphorylation.
• In vitro studies assessing FGL's impact on glial cell activation markers (MHCII, CD40) induced by aging or IFNgamma, and the role of IGF-1.

Main Results:

• FGL administration reversed age-related decline in hippocampal IGF-1 and abrogated the increase in IFNgamma.
• FGL promoted IGF-1 release from primary neurons, which was crucial for neuronal Akt phosphorylation and CD200 ligand expression.
• FGL attenuated glial activation markers (MHCII, CD40) induced by aging and IFNgamma, an effect dependent on IGF-1.

Conclusions:

• FGL corrects age-related imbalances in hippocampal IGF-1 and IFNgamma, thereby attenuating glial cell activation.
• FGL acts via an IGF-1-dependent mechanism to influence neuronal CD200 ligand expression and subsequently modulate glial activation status.
• These findings highlight FGL as a potential therapeutic agent for age-related neuroinflammation.